Anti Endomysial Antibody - IgA IFA

A positive IgA endomysial antibody indicates a strong immune response against intestinal connective tissue and is highly specific for celiac disease. It strongly suggests active gluten‑sensitive enteropathy, especially when tissue transglutaminase IgA is also elevated. Confirmation usually requires duodenal biopsy (or pediatric criteria) while on a gluten‑containing diet. IgA deficiency can affect results, so clinicians interpret alongside symptoms and other tests.

The cost of an EMA (endomysial antibody) test varies by country and provider. On public health systems it’s typically covered if ordered by a clinician. In private labs it ranges roughly: United States $30–200, United Kingdom £30–80, India ₹500–1,500. Prices depend on laboratory, location and whether bundled with other celiac serology; insurance or referrals may reduce out‑of‑pocket cost.

In active celiac disease, specific IgA autoantibodies (anti‑tissue transglutaminase and anti‑endomysial IgA) are typically elevated and used for diagnosis. However, total serum IgA can be normal or low in a minority (selective IgA deficiency), which may cause false‑negative IgA tests; clinicians therefore check total IgA and may use IgG‑based tests or duodenal biopsy if IgA deficiency is present.

IgA endomysial antibody testing costs vary by country and lab. Typical private ranges: India ~₹700–2,000; United States ~$50–200; United Kingdom: usually free if NHS‑requested but about £30–£150 privately. Prices depend on whether it’s ordered alone or in a serology panel, the laboratory method, and insurance or public-health coverage. Check your lab for exact pricing.

A positive IgA test means immunoglobulin A antibodies were detected, indicating a mucosal or systemic immune response. Interpretation depends on the specific test (infection, autoimmune marker, or total IgA). It can signify recent/ongoing infection, autoimmune disease, or—less commonly—an IgA-producing plasma-cell disorder. Your clinician will correlate symptoms, order confirmatory/specific tests and recommend treatment or specialist referral as needed.

Celiac disease has a strong genetic component: nearly all patients carry HLA‑DQ2 or HLA‑DQ8 genes, which are necessary but not sufficient for disease. Many carriers never develop celiac disease; other non‑HLA genes, environmental triggers (gluten exposure, infections), and immune factors contribute. First‑degree relatives have about a 10% risk versus roughly 1% in the general population.